Fig. 1: NASH progression is associated with increased, activated CD8+PD1+ T cells.
From: NASH limits anti-tumour surveillance in immunotherapy-treated HCC
a, CD8 and PD1 staining (right) and quantification (left) of T cells from mice fed normal diet (ND), CD-HFD or western-style diet with trans fat (WD-HTF) by immunohistochemistry. b, Immunofluorescence-based detection of PD1 (green), CD8 (red) and CD4 (yellow) cells. Scale bar, 100 μm. c, GSEA of hepatic CD8+PD1+ T cells sorted from TCRβ+ cells by mass spectrometry. FDR, false discovery rate; NES, normalized enrichment score. d–f, t-distributed stochastic neighbour embedding (tSNE) of TCRβ+ cells (d), differential gene expression by scRNA-seq (e) and scheme for experiment (f): mice were fed CD-HFD for 13 months and then treated with anti-PD1 for 8 weeks before measurement of tumour incidence. Mem, memory CD4 T cells. g, Livers from treated and untreated mice after CD-HFD. Arrowheads, tumours or lesions. Scale bar, 10 mm. h, Quantification of CD8+ cell in liver by immunohistochemistry. Details of sample sizes, biological replicates and statistical tests are given in Methods and Source Data. a, h, P values shown above brackets.
